Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease
Movement Disorders, 07/01/09
Lee JY et al. – Variants of DRD3 p.S9G and GRIN2B c.366C>G may be associated with the appearance of of impulse control and related behaviors (ICRB) in Parkinson's disease (PD).
Methods- Study of whether allelic variants of dopamine receptor, glutamate receptor, and serotonin transporter genes are associated with appearance of ICRB in PD with dopamine replacement therapy (DRT)
- Survey of ICRB in consecutive Korean pts with PD treated with stable DRT using modified Minnesota Impulsive Disorders Interview over 4 mo
- Subjects: 404 pts who completed interview and 559 Korean healthy normal controls
- Genotyping for variants of DRD3 p.S9G, DRD2 Taq1A, GRIN2B c.366C>G, c.2664C>T and c.-200T>G, and promoter region of the serotonin transporter gene (5-HTTLPR)
- Behavioral abnormalities suggestive of ICRB (compulsive buying, gambling, sexual behavior, eating, punding) in 14.4% of pts
- DRD2 and 5-HTTLPR variants not associated with risk of developing ICRB
- AA genotype of DRD3 p.S9G and CC genotype of GRIN2B c.366C>G more frequent in ICRB vs nonaffected pts
- After controlling for clinical variables in multivariate analysis, carriage of either AA genotype of DRD3 or CC genotype of GRIN2B identified as independent risk factor for ICRB
Today in Movement Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Paraplegia Following Image-Guided Transforaminal Lumbar Spine Epidural Steroid Injection: Two Case Reports
Pain Medicine, 10/29/09
Progression of Parkinson's disease in the clinical phase: potential markers
The Lancet Neurology, 11/12/09
A comparison of treatment thresholds in two large Parkinsons disease clinical trial cohorts
Movement Disorders, 11/17/09
Sponsor
Article Search
Sponsor


See Latest Articles


